Further supply disruption of Genzyme's Cerezyme and Fabrazyme leads EMEA to give new temporary treatment recommendations; but no problems with Myozyme
Troubled US biotech firm Genzyme has advised the European Union health regulator that the supply shortages of its rare disease drugs Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) are expected to continue at least until the end of September 2010, because of a new manufacturing problem.
Responding, the European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) noted that temporary treatment recommendations to manage patients relying on these medicines during the ongoing supply shortages have been in place since June 2009 and have been regularly updated.
Patients could be switched to Shire's Replagal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze